The European market has shown resilience with the pan-European STOXX Europe 600 Index ending 0.65% higher, buoyed by easing trade tensions and slowing inflation in key economies, which may prompt further monetary easing by the European Central Bank. In this context of potential expansion and shifting economic policies, high-growth tech stocks become particularly intriguing for investors seeking opportunities that align with evolving market dynamics and technological advancements.

Click here to see the full list of 228 stocks from our European High Growth Tech and AI Stocks screener.

Here's a peek at a few of the choices from the screener.

★★★★★☆

Oryzon Genomics S.A. is a clinical-stage biopharmaceutical company focused on developing epigenetics-based therapeutics for cancer and CNS disorders, with a market cap of €226.34 million.

Operations: Oryzon Genomics specializes in discovering and developing epigenetics-based therapeutics targeting cancer and CNS disorders.

Oryzon Genomics, a trailblazer in epigenetic therapies, is making significant strides with an impressive 49.3% annual revenue growth forecast. Despite its current unprofitability, the company’s strategic focus on R&D (13.26 million EUR allocated to the VANDAM project) underscores its commitment to addressing rare neurodevelopmental disorders and neuroendocrine tumors through precision medicine. The recent 15 million EUR grant for this project enhances Oryzon's potential in pioneering treatments that could revolutionize patient care in these underserved areas. Additionally, their involvement in high-profile clinical trials like the Phase I/II trial of iadademstat for small cell lung cancer further exemplifies their innovative approach within the biotech sector. With expected profitability and earnings growth of 50.17% per annum over the next three years, Oryzon is positioned to leverage its scientific advancements into commercial success.